Current research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing significant outcomes in treating obesity and type 2 condition. Initial data suggest a unique process contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/